22P A comparison of new ESGO-ESTRO-ESP endometrial risk classification with previous classification in predicting outcome

BackgroundThe new ESGO-ESTRO-ESP 2020 risk classification system (molecular classification unknown) has allocated fewer patients to the high-risk group compared to the previous risk stratification system in 2016. The study aims to clinically validate the new system in predicting the outcome compared to the previous one.MethodsWe retrospectively analyzed the data of 684 patients treated between 2009 and 2013 for carcinoma endometrium in a tertiary care oncology center. The three years overall survival (OS) and disease-free survival (DFS) estimates were generated independently using the Kaplan Meier method for the new and previous classification system. Akaike information criterion and concordance index was calculated between both staging systems to identify better predictive model.ResultsTable: 22PESGO 2016 and ESGO-2020 cross-tabulationESGO-2020TotalLowIntermediateHigh- IntermediateHighAdvancedESGO 2016Low2160000216Intermediate08100081High-Intermediate05440058High011241580283Advanced00024446Total21613612816044684 Open table in a new tab ConclusionsThe new 2020 risk stratification appears better predictive of survival events.Legal entity responsible for the studyInstitutional Review Board, Regional Cancer Centre, Thiruvananthapuram.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. BackgroundThe new ESGO-ESTRO-ESP 2020 risk classification system (molecular classification unknown) has allocated fewer patients to the high-risk group compared to the previous risk stratification system in 2016. The study aims to clinically validate the new system in predicting the outcome compared to the previous one. The new ESGO-ESTRO-ESP 2020 risk classification system (molecular classification unknown) has allocated fewer patients to the high-risk group compared to the previous risk stratification system in 2016. The study aims to clinically validate the new system in predicting the outcome compared to the previous one. MethodsWe retrospectively analyzed the data of 684 patients treated between 2009 and 2013 for carcinoma endometrium in a tertiary care oncology center. The three years overall survival (OS) and disease-free survival (DFS) estimates were generated independently using the Kaplan Meier method for the new and previous classification system. Akaike information criterion and concordance index was calculated between both staging systems to identify better predictive model. We retrospectively analyzed the data of 684 patients treated between 2009 and 2013 for carcinoma endometrium in a tertiary care oncology center. The three years overall survival (OS) and disease-free survival (DFS) estimates were generated independently using the Kaplan Meier method for the new and previous classification system. Akaike information criterion and concordance index was calculated between both staging systems to identify better predictive model. ResultsTable: 22PESGO 2016 and ESGO-2020 cross-tabulationESGO-2020TotalLowIntermediateHigh- IntermediateHighAdvancedESGO 2016Low2160000216Intermediate08100081High-Intermediate05440058High011241580283Advanced00024446Total21613612816044684 Open table in a new tab ConclusionsThe new 2020 risk stratification appears better predictive of survival events. The new 2020 risk stratification appears better predictive of survival events.